New York has become the first state in the U.S. to mandate health insurance coverage for EpiPens while capping annual out-of-pocket costs at $100, following Governor Kathy Hochul's signing of a landmark bill.
The legislation, which takes effect January 1, 2026, requires insurance companies to cover a minimum of two epinephrine auto-injectors per patient annually. This move addresses the staggering 600% price increase of EpiPens since 2007, with current costs exceeding $600 for a two-pack.
"When every second counts, the last thing New Yorkers should have to worry about is whether they can afford the medication they need to survive an anaphylactic reaction," stated Governor Hochul upon signing the bill.
The law comes as welcome relief for individuals with severe allergies who depend on these lifesaving devices. With EpiPens having approximately 12-month shelf lives, patients must replace them yearly regardless of use. The soaring costs have forced many to make dangerous choices, including using expired devices or postponing prescription renewals.
Receiving strong bipartisan support, the bill specifically targets commercial health insurance plans. By establishing this coverage mandate and cost ceiling, New York sets a precedent for other states in addressing the accessibility of emergency allergy medication.
This progressive legislation shifts focus toward patient welfare rather than pharmaceutical profits, offering New Yorkers with severe allergies both financial relief and peace of mind regarding their access to this emergency treatment.